Evidence map›Paper›PMID 36878478›Full record

ArticleJMIR public health and surveillance2023

Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit.

Christos D Argyropoulos, Janina Leckler, Jon Salmanton-García, Marinos Constantinou, Alexandra Alexandrou, Sophia Themistocleous, Evgenia Noula, George Shiamakkides, Andria Nearchou, Fiona A Stewart and 43 more

Abstract read
In one paragraph

Article in JMIR public health and surveillance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors.

Christos D ArgyropoulosSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0002-2090-2162
Janina LecklerCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-8488-4338
Jon Salmanton-GarcíaCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-6766-8297
Marinos ConstantinouSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0002-3502-8041
Alexandra AlexandrouSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0009-0003-9212-4288
Sophia ThemistocleousSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0003-3561-0004
Evgenia NoulaSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0009-0008-5799-2289
George ShiamakkidesSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0003-2982-169X
Andria NearchouSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0009-0009-0279-0521
Fiona A StewartCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-1029-5768
Kerstin AlbusCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0003-1124-4310
Markela KoniordouCollaborative Center for Clinical Epidemiology and Outcomes Research, Athens, Greece.ORCID 0000-0002-6034-1291
Ioannis KopsidasCollaborative Center for Clinical Epidemiology and Outcomes Research, Athens, Greece.ORCID 0000-0001-6499-4807
Orly SpivakMinistry of Health of Israel, Jerusalem, Israel.ORCID 0000-0002-1736-6696
Margot HellemansVAXINFECTIO, Centre of Evaluation of Vaccination, Faculty of Medicine and Health Science, Universiteit Antwerpen, Antwerp, Belgium.ORCID 0009-0005-2926-1559
Greet HendrickxVAXINFECTIO, Centre of Evaluation of Vaccination, Faculty of Medicine and Health Science, Universiteit Antwerpen, Antwerp, Belgium.ORCID 0000-0002-0099-272X
Ruth Joanna DavisInfectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.ORCID 0000-0001-9364-6983
Anna Maria AzziniInfectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.ORCID 0000-0002-7148-2559
Paula Valle SimonHospital La Paz Institute for Health Research, Madrid, Spain.ORCID 0000-0002-3399-9725
Antonio Javier Carcas-SansuanHospital La Paz Institute for Health Research, Madrid, Spain.ORCID 0000-0003-1823-4174
Helena Hervius AsklingDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-5155-9726
Sirkka VeneDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8655-5845
Jana Baranda PrellezoCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-9060-9228
Elena Álvarez-BarcoCentre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Dublin, Ireland.ORCID 0000-0002-4903-9171
Alan J MackenCentre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Dublin, Ireland.ORCID 0000-0003-3320-8767
Romina Di MarzoEuropean Vaccine Initiative, Heidelberg, Germany.ORCID 0000-0002-8715-0348
Catarina LuísEuropean Vaccine Initiative, Heidelberg, Germany.ORCID 0000-0003-2748-4087
Ole F OlesenEuropean Vaccine Initiative, Heidelberg, Germany.ORCID 0000-0002-3025-2466
Jesus A Frias IniestaHospital La Paz Institute for Health Research, Madrid, Spain.ORCID 0000-0001-9538-9677
Imre BartaNational Koranyi Institute for Pulmonology, Budapest, Hungary.ORCID 0000-0003-0067-5166
Krisztina TóthNational Koranyi Institute for Pulmonology, Budapest, Hungary.ORCID 0009-0009-1559-5581
Murat AkovaDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Haceteppe University, Ankara, Turkey.ORCID 0000-0002-6904-9473
Marc M J BontenJulius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.ORCID 0000-0002-9095-9201
Miriam Cohen-KandliMinistry of Health of Israel, Jerusalem, Israel.ORCID 0000-0002-1504-5688
Rebecca Jane CoxInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0002-8341-4078
Lenka SoučkováMasaryk University, Brno, Czech Republic.ORCID 0000-0003-0028-4464
Petr HusaMasaryk University, Brno, Czech Republic.ORCID 0000-0002-9190-2610
Ligita JancorieneInstitute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.ORCID 0000-0001-6488-6312
Odile LaunayInstitut National de la Santé et de la Recherche Médicale - France Recherche Nord & Sud Sida- HIV Hépatites Maladies Infectieuses Émergentes, Paris, France.ORCID 0000-0003-3242-7247
Jens LundgrenCentre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8901-7850
Patrick MallonCentre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Dublin, Ireland.ORCID 0000-0002-4337-6222
Charis ArmeftisSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0009-0007-8091-6711
Laura MarquesCentro Hospitalar Universitário do Porto, Porto, Portugal.ORCID 0000-0002-6446-0319
Pontus NauclerDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8185-2648
Jordi OchandoCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-7037-1681
Evelina TacconelliInfectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.ORCID 0000-0003-2010-4977
Pierre van DammeVAXINFECTIO, Centre of Evaluation of Vaccination, Faculty of Medicine and Health Science, Universiteit Antwerpen, Antwerp, Belgium.ORCID 0000-0002-8642-1249
Theoklis ZaoutisCollaborative Center for Clinical Epidemiology and Outcomes Research, Athens, Greece.ORCID 0000-0003-0127-6562
Sanne HofstraatUniversity Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.ORCID 0009-0004-5672-2106
Patricia Bruijning-VerhagenUniversity Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.ORCID 0000-0003-4105-9669
Markus ZeitlingerMedizinische Universität Wien, Vienna, Austria.ORCID 0000-0002-1873-3953
Oliver A CornelyCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-9599-3137
Zoi Dorothea PanaSchool of Medicine, European University Cyprus, Nicosia, Cyprus.ORCID 0000-0002-5893-1081

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pan-European VACCELERATE network aims to implement the first transnational harmonized and sustainable vaccine trial Volunteer Registry, being a single entry point for potential volunteers of large-scale vaccine trials across Europe. This work exhibits a set of harmonized vaccine trial-related educational and promotional tools for the general public, designed and disseminated by the pan-European VACCELERATE network.

objectiveThis study primarily aimed to design and develop a standard toolkit to increase positive attitudes and access to trustworthy information for better access and increased recruitment to vaccine trials for the public. More specifically, the produced tools are focused on inclusiveness and equity, and are targeting different population groups, including underserved ones, as potential volunteers for the VACCELERATE Volunteer Registry (older individuals, migrants, children, and adolescents). The promotional and educational material is aligned with the main objectives of the Volunteer Registry to increase public literacy and awareness regarding vaccine-related clinical research or trials and trial participation, including informed consent and legal issues, side effects, and frequently asked questions regarding vaccine trial design.

methodsTools were developed per the aims and principles of the VACCELERATE project, focusing on trial inclusiveness and equity, and are adjusted to local country-wise requirements to improve public health communication. The produced tools are selected based on the cognitive theory, inclusiveness, and equity of differently aged and underrepresented groups, and standardized material from several official trustworthy sources (eg, COVID-19 Vaccines Global Access; the European Centre for Disease Prevention and Control; the European Patients' Academy on Therapeutic Innovation; Gavi, the Vaccine Alliance; and the World Health Organization). A team of multidisciplinary specialists (infectious diseases, vaccine research, medicine, and education) edited and reviewed the subtitles and scripts of the educational videos, extended brochures, interactive cards, and puzzles. Graphic designers selected the color palette, audio settings, and dubbing for the video story-tales and implemented QR codes.

resultsThis study presents the first set of harmonized promotional and educational materials and tools (ie, educational cards, educational and promotional videos, extended brochures, flyers, posters, and puzzles) for vaccine clinical research (eg, COVID-19 vaccines). These tools inform the public about possible benefits and disadvantages of trial participation and build confidence among participants about the safety and efficacy of COVID-19 vaccines and the health care system. This material has been translated into several languages and is intended to be freely and easily accessible to facilitate dissemination among VACCELERATE network participant countries and the European and global scientific, industrial, and public community.

conclusionsThe produced material could help fill knowledge gaps of health care personnel, providing the appropriate future patient education for vaccine trials, and tackling vaccine hesitancy and parents' concerns for potential participation of children in vaccine trials.

Indexed as

COVID-19Health CommunicationVaccinesAdolescentAgedChildCOVID-19 VaccinesEuropeHumansCOVID-19 VaccinesVaccinescampaigncoronavirusCOVID-19educational materialhealth communicationhealth promotionhesitancymisinformationpandemicpatient educationpromotional materialpublic healthSARS-CoV-2vaccinationvaccinevaccine trialsvolunteer registry

Identifiers

PMID36878478
PMCPMC10131613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.